Atossa Genetics is a biotechnology business based in the US. Atossa Genetics shares (ATOS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.69 – a decrease of 7.08% over the previous week. Atossa Genetics employs 12 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.69 |
|---|---|
| 52-week range | $0.71 - $2.31 |
| 50-day moving average | $0.87 |
| 200-day moving average | $1.22 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.21 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.7408 from 2025-03-11
| 1 week (2025-03-06) | -1.29% |
|---|---|
| 1 month (2025-02-14) | -10.77% |
| 3 months (2024-12-13) | -33.86% |
| 6 months (2024-09-13) | -51.26% |
| 1 year (2024-03-13) | -41.21% |
|---|---|
| 2 years (2023-03-13) | 13.97% |
| 3 years (2022-03-11) | 1.21 |
| 5 years (2020-03-13) | 0.91 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -20.35% |
| Return on equity TTM | -31.3% |
| Profit margin | 0% |
| Book value | $0.59 |
| Market Capitalization | $94.4 million |
TTM: trailing 12 months
We're not expecting Atossa Genetics to pay a dividend over the next 12 months.
Atossa Genetics's shares were split on a 1:12 basis on 19 April 2018 . So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Atossa Genetics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Atossa Genetics shares which in turn could have impacted Atossa Genetics's share price.
Over the last 12 months, Atossa Genetics's shares have ranged in value from as little as $0.7064 up to $2.31. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atossa Genetics's is 1.201. This would suggest that Atossa Genetics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Atossa Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.
Spot dogecoin ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
We analyzed a number of bitcoin ETFs to determine which are best to invest in.
Arrived offers a simple way to invest in real estate rental properties.
3 Northwestern Mutual wealth management alternatives to consider.
Investing in mutual funds offers instant diversification. Learn more.
What you need to know about investing in the leading indicator for the overall US stock market.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.